Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 10/20 | 0.71 |
| ▸ | NPY1R | P25929 | 10/20 | 0.71 |
| ▸ | NPY4R | P50391 | 8/20 | 0.71 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.71 |
| ▸ | TFPI | P10646 | 4/20 | 0.66 |
| ▸ | RAMP3 | O60896 | 3/20 | 0.62 |
| ▸ | CALCR | P30988 | 3/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30574249 | 1.00 | NPY2R (0.71) | NPY2RNPY1RNPY4RNPY5RTFPI | |
| SCHEMBL30574250 | 0.97 | NPY2R (0.72) | NPY2RNPY1RNPY4RNPY5RTFPI | |
| SCHEMBL30574247 | 0.95 | NPY2R (0.74) | NPY2RNPY1RNPY4RNPY5RTFPI | |
| SCHEMBL29360416 | 0.94 | NPY2R (0.66) | NPY2RNPY1RNPY4RNPY5RTFPI | |
| SCHEMBL4331434 | 0.90 | NPY2R (0.75) | NPY2RNPY1RNPY4RNPY5RTFPI | |
| SCHEMBL29359777 | 0.89 | NPY2R (0.63) | NPY2RNPY1RNPY4RNPY5RTFPI | |
| SCHEMBL15669203 | 0.88 | NPY2R (0.74) | NPY2RNPY1RNPY4RNPY5RTFPI | |
| SCHEMBL15669269 | 0.88 | NPY2R (0.76) | NPY2RNPY1RNPY4RNPY5RTFPI | |
| SCHEMBL9979655 | 0.88 | NPY2R (0.69) | NPY2RNPY1RNPY4RNPY5RTFPI | |
| SCHEMBL238214 | 0.87 | NPY2R (0.69) | NPY2RNPY1RNPY4RNPY5RTFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117529496-A | Small molecule regulated cell signaling expression system | 欧特佩斯生物公司 | 2024-02-06 | — | — | CN | claimed |
| US-20220025003-A1 | REAGENTS AND METHODS FOR CONTROLLING PROTEIN FUNCTION AND INTERACTION | HOWARD HUGHES MEDICAL INSTITUTE | 2022-01-27 | — | — | US | claimed |
| US-20250268938-A1 | SMALL MOLECULE-REGULATED CELL SIGNALING EXPRESSION SYSTEM | OUTPACE BIO, INC. | 2025-08-28 | — | — | US | disclosed |
| US-20250243247-A1 | CHIMERIC ANTIGEN RECEPTOR (CAR) MODULATION | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-07-31 | — | — | US | disclosed |
| US-20250188125-A1 | De novo Design of Protein Switches | UNIVERSITY OF WASHINGTON | 2025-06-12 | — | — | US | disclosed |
| US-12304927-B2 | De novo design of protein switches | UNIVERSITY OF WASHINGTON (US) | 2025-05-20 | — | — | US | disclosed |
| US-12202863-B2 | Chimeric antigen receptor (CAR) modulation | TRUSTEES OF BOSTON UNIVERSITY (US) | 2025-01-21 | — | — | US | disclosed |
| US-12180485-B2 | Repressible control of gene expression | TRUSTEES OF BOSTON UNIVERSITY (US) | 2024-12-31 | — | — | US | disclosed |
| CN-117529496-A | Small molecule regulated cell signaling expression system | 欧特佩斯生物公司 | 2024-02-06 | — | — | CN | disclosed |
| US-20230279406-A1 | INDUCIBLE CONTROL OF GENE EXPRESSION | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-09-07 | — | — | US | disclosed |
| US-20230241026-A1 | NOVEL DRUG-CONTROLLED SYSTEMS AND USES THEREOF | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-08-03 | — | — | US | disclosed |
| US-11660288-B2 | Drug-controlled systems and uses thereof | TRUSTEES OF BOSTON UNIVERSITY (US) | 2023-05-30 | — | — | US | disclosed |
| US-20220226485-A1 | DE NOVO DESIGN OF PHOSPHORYLATION INDUCIBLE PROTEIN SWITCHES (PHOSPHO-SWITCHES) | UNIVERSITY OF WASHINGTON | 2022-07-21 | — | — | US | disclosed |
| US-20220218752-A1 | LOCKR-MEDIATED RECRUITMENT OF CAR T CELLS | FRED HUTCHINSON CANCER CENTER | 2022-07-14 | — | — | US | disclosed |
| EP-3983428-A1 | DE NOVO DESIGN OF PHOSPHORYLATION INDUCIBLE PROTEIN SWITCHES (PHOSPHO-SWITCHES) | University of Washington (US) | 2022-04-20 | — | — | EP | disclosed |
| CN-114302895-A | Novel design of phosphorylation-induced protein switch (phosphate switch) | 华盛顿大学 | 2022-04-08 | — | — | CN | disclosed |
| US-20220098246-A1 | CHIMERIC ANTIGEN RECEPTOR (CAR) MODULATION | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-03-31 | — | — | US | disclosed |
| US-20220073565-A1 | DE NOVO DESIGN OF PROTEIN SWITCHES FOR TUNABLE CONTROL OF PROTEIN DEGRADATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-03-10 | — | — | US | disclosed |
| EP-3947432-A1 | CHIMERIC ANTIGEN RECEPTOR (CAR) MODULATION | Trustees of Boston University (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20220025003-A1 | REAGENTS AND METHODS FOR CONTROLLING PROTEIN FUNCTION AND INTERACTION | HOWARD HUGHES MEDICAL INSTITUTE | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11660288-B2 | Drug-controlled systems and uses thereof | ATF4, MRPL21, SARS1 | NPY2R 2590/4885NPY1R 2831/4885NPY4R 2348/4885 |
| US-20230241026-A1 | NOVEL DRUG-CONTROLLED SYSTEMS AND USES THEREOF | ATF4, MRPL21, TMPRSS2 | NPY2R 1912/4885NPY1R 2306/4885NPY4R 1875/4885 |
| US-20250243247-A1 | CHIMERIC ANTIGEN RECEPTOR (CAR) MODULATION | HAVCR2, CPB1, CTRL | NPY2R 3151/4885NPY1R 2576/4885NPY4R 3416/4885 |
| US-20220098246-A1 | CHIMERIC ANTIGEN RECEPTOR (CAR) MODULATION | HAVCR2, CPB1, CTRL | NPY2R 3151/4885NPY1R 2576/4885NPY4R 3416/4885 |
| US-20220025003-A1 | REAGENTS AND METHODS FOR CONTROLLING PROTEIN FUNCTION AND INTERACTION | HAVCR2, GTF3C4, GTF3C1 | NPY2R 4705/4885NPY1R 4747/4885NPY4R 4318/4885 |
| US-12202863-B2 | Chimeric antigen receptor (CAR) modulation | HAVCR2, CPB1, CTRL | NPY2R 3151/4885NPY1R 2576/4885NPY4R 3416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.